Flexion Therapeutics

Flexion Therapeutics advances drug candidates through clinical proof of concept and beyond, in partnership with pharmaceutical and biotechnology companies. By providing expertise and sharing risk, Flexion effectively expands the portfolios of its partners.

Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 3.54% and -4.83%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Flexion Therapeutics (FLXN) Reports Q1 Loss, Lags Revenue Estimates

Zilretta, the only approved corticosteroid for extended-release use, was approved for one-time use only.

News for Flexion Therapeutics Stock (FLXN)